MAPT and Alzheimer disease: The availability of established safety profiles and regulatory approval enables rapid clinical investigation through expedited development pathways, though the therapeutic hypothesis requires systematic validation in AD-specific preclinical models assessing effects on amyloid pathology, tau phosphorylation, neuroinflammation, and cognitive outcomes.